BFRINasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BFRIW
Biofrontera Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.81−0.02 (-1.94%)
Close on Oct 19, 2026
- Market cap
- $10.41M
- P/E (TTM)
- –
- Dividend yield
- –
Biofrontera statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Biofrontera | Industry median |
|---|---|---|
| Market Cap | $11.97M | $166.30M |
| Enterprise Value | $7.31M | $88.19M |
| PS Ratio | 0.26 | 3.65 |
| PB Ratio | 2.01 | 2.03 |
| P/TBV Ratio | 3.53 | 2.29 |
Enterprise value
| Measure | Biofrontera | Industry median |
|---|---|---|
| EV / Sales | 0.16 | 2.51 |
Income (trailing twelve months)
| Measure | Biofrontera | Industry median |
|---|---|---|
| Revenue | $46.18M | $58.34M |
| Operating Income | -$6.56M | -$21.40M |
| Pretax Income | -$6.34M | -$14.34M |
| Net Income | -$6.37M | -$22.46M |
| EBITDA | -$6.56M | -$16.91M |
| EPS (Diluted) | -$0.60 | -$0.83 |
Margins
| Measure | Biofrontera | Industry median |
|---|---|---|
| Operating Margin | -14.2% | -44.0% |
| Pretax Margin | -13.7% | -13.3% |
| Profit Margin | -13.8% | -40.2% |
| EBITDA Margin | -14.2% | -30.2% |
| FCF Margin | -17.2% | -9.27% |
Returns
| Measure | Biofrontera | Industry median |
|---|---|---|
| Return on Equity (ROE) | -988.4% | -53.2% |
| Return on Assets (ROA) | -28.8% | -40.9% |
| Return on Capital Employed (ROCE) | -48.5% | -38.1% |
Growth
| Measure | Biofrontera | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 17.8% | 5.96% |
| Revenue Growth (3Y CAGR) | 13.3% | 2.25% |
| Revenue Growth (5Y CAGR) | 17.2% | 6.48% |
Balance sheet
| Measure | Biofrontera | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $4.66M | $61.43M |
| Net Cash (Debt) | $4.66M | $15.35M |
| Net Cash Per Share | $0.31 | $0.66 |
| Equity (Book Value) | $5.96M | $49.09M |
| Book Value Per Share | $0.40 | $1.37 |
| Tangible Book Value | $3.39M | $23.52M |
| Working Capital | $1.89M | $76.81M |
Financial position
| Measure | Biofrontera | Industry median |
|---|---|---|
| Current Ratio | 1.18 | 3.34 |
| Quick Ratio | 0.97 | 2.44 |
Cash flow (trailing twelve months)
| Measure | Biofrontera | Industry median |
|---|---|---|
| Operating Cash Flow | -$7.93M | -$12.35M |
| Capital Expenditures | -$3.00K | -$1.08M |
| Free Cash Flow | -$7.93M | -$20.22M |
| FCF Per Share | -$0.53 | -$0.42 |
Efficiency
| Measure | Biofrontera | Industry median |
|---|---|---|
| Asset Turnover | 2.09 | 0.39 |
| Revenue Per Employee | $501.90K | $404.87K |
| Profits Per Employee | -$69.18K | -$703.34K |
| Employee Count | 92 | 74 |
Dividends and yields
| Measure | Biofrontera | Industry median |
|---|---|---|
| Earnings Yield | -53.2% | -23.3% |
| FCF Yield | -66.3% | -8.72% |
Shares
| Measure | Biofrontera | Industry median |
|---|---|---|
| Shares Outstanding | 14,852,400 | 58,127,000 |
| Shares Change (YoY) | 49.0% | 10.9% |
| Shares Change (QoQ) | 19.6% | 0.54% |
| Float | 11,331,200 | 49,136,700 |
| Shares Held by Insiders | 23.7% | 11.6% |
| Shares Held by Institutions | 19.7% | 59.4% |
Scores
| Measure | Biofrontera | Industry median |
|---|---|---|
| Altman Z-Score | -6.25 | -0.22 |
| Piotroski F-Score | 3 | 4 |
Calculated by StockData from Biofrontera's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.